Patricia A. Baxter, MD, MBA
- Cancer and Blood Disorders
Director, Clinical Research Operations, Cancer and Hematology Center
Associate Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
Office location:
1102 Bates Avenue
Houston, TX 77030
Get to know Patricia A. Baxter, MD, MBA
Personal Statement
Dr. Patricia Baxter's area of interest and expertise is in pediatric neuro-oncology, developmental therapeutics and palliative care. She completed her pediatric hematology-oncology fellowship training at Texas Children’s Hospital in 2009.
Dr. Baxter has extensive experience in the areas of clinical pharmacology and clinical trial design. As the Associate Director of Clinical Research Operations at one of the largest pediatric cancer centers in the country, she provides clinical research education to faculty, nurses and research staff, reviews new protocols for feasibility, and implements processes in order to maintain the highest quality of data.
In addition, she is board certified in Clinical Pharmacology, and obtained a Master’s of Science degree in clinical research from Baylor College of Medicine.
Her training on the K12 faculty training grant and research experiences have been enriched by the incredible mentorship of both Drs. Susan Blaney and Stacey Berg, two of the national leaders in developmental therapeutics. This mentorship was been vital in the development of PBTC-033, a phase I/II study evaluating Veliparib in combination with radiation and temozolomide in the treatment of patients with DIPG.
Her expertise in clinical trial design and conduct was recognized by the Pediatric Brain Tumor Consortium and resulted in her appointment to leadership positions, including: the Chair of the New Agent Committee where she works to identify new agents for evaluation and develop study concepts, membership on the Toxicity and Monitoring Committee and the Quality Assurance Committee, as well as appointment to the National Institutes of Health (NIH) Brain Malignancy Steering Committee as a Pediatric Brain Tumor Consortium (PBTC) representative.
Her career goal is to improve the prognosis and quality of life of patients with brain tumors. The training and mentorship she has received through the K12, her experiences as a cooperative group study chair, her expertise in clinical research operations and her participation in clinical research quality oversight have allowed her to develop expertise as a clinical researcher.
Dr. Patricia Baxter's interests are in pre-clinical and clinical research studies of new therapies for patients with brain tumors.
Clinical Interests
- Pediatric brain tumors
- Pediatric solid tumors
Research Interests
- Pre-clinical and clinical research studies of new therapies for patients with brain tumors
Education
| School | Education | Degree | Year |
|---|---|---|---|
| Baylor College of Medicine | Masters | Master of Science, Clinical Investigation, Clinical Scientist Training Program | 2012 |
| Rice University, Jones Graduate School of Business | Masters | Master of Business Administration | 2009 |
| Baylor College of Medicine | Fellowship | Pediatric Hematology-Oncology | 2009 |
| A.I. DuPont Hospital for Children | Residency | Pediatrics | 2006 |
| Jefferson Medical College | Medical School | Doctor of Medicine | 2002 |
Organizations
| Organization Name | Role |
|---|---|
| American Society of Clinical Oncology (ASCO) | Member |
| Children's Oncology Group (COG) | Member |
Board Certifications
American Board of Clinical Pharmacology
American Board of Pediatrics
American Board of Pediatrics - Palliative Care and Hospice Medicine
American Board of Pediatrics - Hematology/Oncology
Awards
2022 Star Faculty Award for Excellence in Clinical Care, Baylor College of Medicine
2019 RRO Quarterly Clinical Research Award, Texas Children’s Hospital
2015 BCM Department of Pediatrics Education Pilot Award
2014 BCM Department of Pediatrics Education Pilot Award
2013 Pediatric Oncology Research Faculty Training Program, NIH K-12 Award
2012 Pediatric Oncology Research Faculty Training Program, NIH K-12 Award
2011 Pediatric Oncology Research Faculty Training Program, NIH K-12 Award
2010 Pediatric Oncology Research Faculty Training Program, NIH K-12 Award
2010 Hyundai Hope on Wheels Scholar
2010 Pediatric Oncology Fellowship Research Training Program, NIH T-32 Award
2009 Hyundai Hope on Wheels Scholar
2009 Pediatric Oncology Fellowship Research Training Program, NIH T-32 Award
2009 ASCO Young Investigator Award
2009 Award for Presentation of Research, Texas Children’s Hospital Cancer Center Symposium
2008 Bone Marrow Transplant Oral Presentation Award, Center for Cell and Gene Therapy
2008 Tumor Board Presentation Award, Texas Children’s Cancer Center
2008 Chief Fellow, Pediatric Hematology-Oncology, Baylor College of Medicine
2008 Pediatric Oncology Fellowship Research Training Program, NIH T-32 Award
2008 Pediatric Research Training Program, NIH T-32 Award
2007 Pediatric Research Training Program, NIH T-32 Award
2007 Pediatric Research Training Program, NIH T-32 Award
2005 Chief Fellow, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
2005 Senior Resident Teaching Award
* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.
Research Area:
Cancer Survivorship
Developmental therapeutics
Dr. Patricia Baxter's research focus has been on examining the role of BMI-1 in pediatric brain tumors.
Her fellowship research training was conducted in the laboratory of former faculty member, Xiao-Nan Li, MD PhD, where she utilized his orthotopic xenograft CNS models for pre-clinical screening of novel therapeutics agents. She continued to work closely with Xiao-Nan and this collaboration has been extremely helpful in bridging basic brain tumor biology and the clinic. The lab serves as the core lab for preclinical testing for the Pediatric Pre-Clinical Testing Consortium, which allows her team to generate the necessary pre-clinical data to quickly move forward to the clinic